| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 03/04/2010 | US20100056615 Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders |
| 03/04/2010 | US20100056542 Compounds, compositions and methods of using same for modulating uric acid levels |
| 03/04/2010 | US20100056506 Substituted 2-amino-fused heterocyclic compounds |
| 03/04/2010 | US20100056483 Methods and compositions for the treatment and prevention of bone loss |
| 03/04/2010 | US20100056481 Crystalline forms of zoledronic acid |
| 03/04/2010 | US20100056465 Compounds, compositions and methods of using same for modulating uric acid levels |
| 03/04/2010 | US20100056464 Compounds, compositions and methods of using same for modulating uric acid levels |
| 03/04/2010 | US20100055184 Hydrogels for vocal cord and soft tissue augmentation and repair |
| 03/04/2010 | US20100055183 Trimeprazine and ethopropazine derivatives for promoting bone growth |
| 03/04/2010 | US20100055159 Percutaneous preparations |
| 03/04/2010 | US20100055150 Method and composition for treatment of skeletal dysplasias |
| 03/04/2010 | US20100055114 Use of integrin alpha 10 binding antibody to modulate extracellular matrix (cartilage) turnover |
| 03/04/2010 | US20100055080 Bioadhesive directed somatic cell therapy |
| 03/04/2010 | DE202008017680U1 Zubereitungen mit Hagebuttenextrakten Preparations with rosehip extracts |
| 03/04/2010 | CA2735279A1 Anti-cd5 antibodies |
| 03/04/2010 | CA2732438A1 Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| 03/03/2010 | EP2158319A1 Bone targeted alkaline phosphatase, kits and methods of use thereof |
| 03/03/2010 | EP1891102B1 Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12 |
| 03/03/2010 | EP1743648B1 Method for treating inflammation |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671090 Inhibitors of α4 mediated cell adhesion |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671054 Reverse-turn mimetics and method relating thereto |
| 03/02/2010 | US7671053 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide for treatment of asthma and COPD; purinergic receptors (P2X7) |
| 03/02/2010 | US7670626 Encapsulated bioactive bisphosphonate such as alendronate including mono- or diglyceride of caproic or capric acid enhancer or surfactant comprising ethylene oxide-propylene oxide block copolymer |
| 03/02/2010 | US7670602 Concatameric immunoadhesion molecule |
| 03/02/2010 | US7670599 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy |
| 03/02/2010 | CA2665501A1 Methods and compositions for the treatment and prevention of bone loss |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 02/25/2010 | WO2010022249A2 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | WO2010022201A2 Folinic acid derivatives for promoting bone growth |
| 02/25/2010 | WO2010022120A1 Human antibodies to human rankl |
| 02/25/2010 | WO2010022083A2 Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
| 02/25/2010 | WO2010022043A2 Targeting of histone deacetylase 2 and protein kinase ck2 for treatment of inflammatory diseases |
| 02/25/2010 | WO2010020981A1 A3 adenosine receptor allosteric modulators |
| 02/25/2010 | WO2010020762A1 1,5-diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists |
| 02/25/2010 | WO2010020647A2 New method for identifying compounds useful for treating and/or preventing disease-associated bone loss |
| 02/25/2010 | WO2010020379A1 Composition for prevention and treatment of allergic and/or inflammatory diseases |
| 02/25/2010 | WO2010001258A3 Inhibition of tumour growth and metastases |
| 02/25/2010 | WO2009158446A3 Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof |
| 02/25/2010 | WO2009148566A3 Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis |
| 02/25/2010 | WO2009140101A3 Imidazopyridine compounds useful as mmp-13 inhibitors |
| 02/25/2010 | WO2009126923A3 Estrogenic extracts of anemarrhena asphodeloides bge from the liliaceae family and uses thereof |
| 02/25/2010 | WO2009115651A3 N-phenyl-imidazo[1,2-a]pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106752A3 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106751A3 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2- a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 02/25/2010 | WO2009106750A3 Derivatives of 6-heterocyclic-imidazo[l,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 02/25/2010 | US20100048702 Prevention of neutrophil recruitment |
| 02/25/2010 | US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 02/25/2010 | US20100048697 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048565 Benzimidazole derivatives |
| 02/25/2010 | US20100048558 Thienopyridines |
| 02/25/2010 | US20100048518 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 02/25/2010 | US20100048506 Composition for treating arthritic disorder |
| 02/25/2010 | US20100048501 Phosphorylated A2A Receptor Agonists |
| 02/25/2010 | US20100048458 Tribonectins |
| 02/25/2010 | US20100047361 Active Principle which is capable of inducing the conversion of inactive TGFb-Latent into active TGFb |
| 02/25/2010 | US20100047350 Osteogenic compositions containing a coloring agent |
| 02/25/2010 | US20100047339 Compositions for the treatment of chronic degenerative inflammatory conditions |
| 02/25/2010 | US20100047333 Modified Peptides and Their Use for the Treatment of Autoimmune Diseases |
| 02/25/2010 | US20100047316 Repair of cartilage tissue using a matrix gel containing chondrocytes |
| 02/25/2010 | US20100047314 Folinic acid derivatives for promoting bone growth |
| 02/25/2010 | US20100047259 Follistatin domain containing proteins |
| 02/25/2010 | US20100047256 Methods |
| 02/25/2010 | US20100047220 Substances |
| 02/25/2010 | US20100047218 Reversible immortalization |
| 02/25/2010 | US20100047181 Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller |
| 02/25/2010 | DE102008036060A1 Zellbasiertes Verfahren und Mittel zum Knochenaufbau Cell-based method and means for bone formation |
| 02/25/2010 | CA2734858A1 Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
| 02/25/2010 | CA2734678A1 New method for identifying compounds useful for treating and/or preventing disease-associated with bone loss |
| 02/25/2010 | CA2733790A1 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/24/2010 | EP2157097A1 Specific binding agents of human angiopoietin-2 |
| 02/24/2010 | EP2157081A1 Indolinones substituted in six locations, their manufacture and their application as medicine |
| 02/24/2010 | EP2155711A1 Substituted benzoylamino-indan-2-carboxylic acids and related compounds |
| 02/24/2010 | EP2155256A1 Novel antibody and use in diagnosis and therapy of arthropathies |
| 02/24/2010 | EP2155233A2 Synthetic peptide materials for joint reconstruction, repair and cushioning |
| 02/24/2010 | EP2155208A1 Disaccharides for the treatment of tendons, ligaments and bones |
| 02/24/2010 | EP2155184A2 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 02/24/2010 | EP2155179A1 Axomadol for treating pain from arthritis |
| 02/24/2010 | EP2029596B1 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same |
| 02/24/2010 | EP1465631B1 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 02/24/2010 | CN201410029Y Five-party information moxibustion paste |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/24/2010 | CN101653604A Anti-ngf antibodies for the treatment of various disorders |
| 02/24/2010 | CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease |
| 02/24/2010 | CN101653436A Omega-3 fatty acids for the treatment of canine ostheoarthritis |
| 02/24/2010 | CN100591225C Composition containing isoflavone of high concentration and having high solubility, and process for producing the same |
| 02/23/2010 | USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction |
| 02/23/2010 | USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 02/23/2010 | US7667052 Bioactive substance |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7667007 αvβ3-specific antibodies |
| 02/23/2010 | US7666913 And isotaxiresinol ether, ester and/or salt analogs; not only inhibits bone resorption but also improves bone formation; plant extracts; lignins; nontoxic; bone disorders |
| 02/23/2010 | US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12 |
| 02/23/2010 | US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics |
| 02/23/2010 | US7666839 Methods of treatment using specific binding agents of human angiopoietin-2 |
| 02/23/2010 | US7666832 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent |